Citations

Showing 10 of 108094 citations.

Surgical Management of Enterovesical Fistula in Crohn’s Disease in the Biologic Era
McKenna, Nicholas P. , Bews, Katherine A. , Mathis, Kellie L. , Kelley, Scott R. , McKenna, Nicholas P , Behm, Kevin T.

Mayo Clinic

Inflammatory Bowel Diseases | June 25, 2022 | Volume: 29 | Issue: 3 | Pages: 480-482

10.1093/ibd/izac133 | PMID 35751558 Get It

Lay SummaryEnterovesical fistula in Crohn’s disease that require surgery may be managed safely laparoscopically with similar morbidity to open repair and a shorter length of stay. Preoperative biologic exposure does not affect surgical morbidity.
Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson’s Disease Affected by COVID-19: A Narrative Review
Suri, Jasjit S. , Maindarkar, Mahesh , Paul, Sudip , Ahluwalia, Puneet , Bhagawati, Mrinalini , Saba, Luca , Faa, Gavino , Saxena, Sanjay , Singh, Inder M. , Chadha, Paramjit S., Turk, Monika, Johri, Amer M. , Khanna, Narendra N. , Višković, Klaudija , Mavrogeni, Sophie , Laird, John R. , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Sockalingam, Meyypan, Saxena, Ajit Kumar , Rathore, Vijay , Fatemi, Mostafa , Krishnan, Padukode R., Omerzu, Tomaž , Naidu, Subbaram, Paraskevas, Kosmas I. , Ruzsa, Zoltán , Fouda, Mostafa M. , Maindarkar, Mahesh A , Mavrogeni, Sophie , Sobel, David W , Tsoulfas, George , Fatemi, Mostafa , Naidu, Subbaram , Paraskevas, Kosmas I , Ruzsa, Zoltan , Fouda, Mostafa M , Misra, Durga Prasanna , Agarwal, Vikas , Protogerou, Athanasios , Faa, Gavino , Paul, Sudip , Bhagawati, Mrinalini , Suri, Jasjit S. , Saba, Luca , Kitas, George D. , Kolluri, Raghu , Sharma, Aditya , Alizad, Azra , Nicolaides, Andrew , Kalra, Mannudeep K.

Mayo Clinic

Diagnostics | June 25, 2022 | Volume: 12 | Issue: 7 | Pages: 1543

10.3390/diagnostics12071543 | PMID 35885449 Get It

Background and Motivation: Parkinson’s disease (PD) is one of the most serious, non-curable, and expensive to treat. Recently, machine learning (ML) has shown to be able to predict cardiovascular/stroke risk in PD patients. The presence of COVID-19 causes the ML systems to become severely non-linear and poses challenges in cardiovascular/stroke risk stratification. Further, due to comorbidity, sample size constraints, and poor scientific and clinical validation techniques, there have been no well-explained ML paradigms. Deep neural networks are powerful learning machines that generalize non-linear conditions. This study presents a novel investigation of deep learning (DL) solutions for CVD/stroke risk prediction in PD patients affected by the COVID-19 framework. Method: The PRISMA search strategy was used for the selection of 292 studies closely associated with the effect of PD on CVD risk in the COVID-19 framework. We study the hypothesis that PD in the presence of COVID-19 can cause more harm to the heart and brain than in non-COVID-19 conditions. COVID-19 lung damage severity can be used as a covariate during DL training model designs. We, therefore, propose a DL model for the estimation of, (i) COVID-19 lesions in computed tomography (CT) scans and (ii) combining the covariates of PD, COVID-19 lesions, office and laboratory arterial atherosclerotic image-based biomarkers, and medicine usage for the PD patients for the design of DL point-based models for CVD/stroke risk stratification. Results: We validated the feasibility of CVD/stroke risk stratification in PD patients in the presence of a COVID-19 environment and this was also verified. DL architectures like long short-term memory (LSTM), and recurrent neural network (RNN) were studied for CVD/stroke risk stratification showing powerful designs. Lastly, we examined the artificial intelligence bias and provided recommendations for early detection of CVD/stroke in PD patients in the presence of COVID-19. Conclusion: The DL is a very powerful tool for predicting CVD/stroke risk in PD patients affected by COVID-19.
Right atrial thrombus in transit
Schumer, Erin M. , Crestanello, Juan A. , Crestanello, Juan A

Mayo Clinic

European Heart Journal | June 25, 2022 | Volume: 43 | Issue: 34 | Pages: 3274-3274

10.1093/eurheartj/ehac346 | PMID 35751530 Get It

Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment
Tremblay, Cécilia , Intorcia, Anthony J., Mariner, Monica, Sue, Lucia I., Arce, Richard, Belden, Christine M. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Atri, Alireza , Adler, Charles H. , Driver‐Dunckley, Erika

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | June 25, 2022 | Volume: 81 | Issue: 8 | Pages: 643-649

10.1093/jnen/nlac042 | PMID 35751438 Get It

Abstract The Alzheimer disease (AD) neuropathological hallmarks amyloid β (Aβ) and tau neurofibrillary (NF) pathology have been reported in the olfactory bulb (OB) in aging and in different neurodegenerative diseases, which coincides with frequently reported olfactory dysfunction in these conditions. To better understand when the OB is affected in relation to the hierarchical progression of Aβ throughout the brain and whether OB pathology might be an indicator of AD severity, we assessed the presence of OB Aβ and tau NF pathology in an autopsy cohort of 158 non demented control and 173 AD dementia cases. OB Aβ was found in less than 5% of cases in lower Thal phases 0 and 1, in 20% of cases in phase 2, in 60% of cases in phase 3 and in more than 80% of cases in higher Thal phases 4 and 5. OB Aβ and tau pathology significantly predicted a Thal phase greater than 3, a Braak NF stage greater than 4, and an MMSE score lower than 24. While OB tau pathology is almost universal in the elderly and therefore is not a good predictor of AD severity, OB Aβ pathology coincides with clinically-manifest AD and might prove to be a useful biomarker of the extent of brain spread of both amyloid and tau pathology.
Fontan Palliation in Patients with Heterotaxy Syndrome: A Five Decade Experience
Stephens, Elizabeth H. , Graham, Gabriel, Dearani, Joseph A. , Cetta, Frank , Dearani, Joseph A. , Niaz, Talha

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | June 25, 2022 | Volume: 13 | Issue: 4 | Pages: 436-442

10.1177/21501351221099944 | PMID 35757949 Get It

Background Patients with heterotaxy syndromes (right and left atrial isomerism) are at high risk of poor outcomes after single-ventricle palliation. However, the long-term outcomes and specific parameters associated with poor outcomes are incompletely understood. Methods A retrospective review was performed of all patients with atrial isomerism who had a Fontan at our institution from 1973 to 2020. Standard demographic, as well as pre-, peri-, and postoperative parameters were collected. Features and outcomes of patients with polysplenia were compared to asplenia. Outcomes were analyzed for effect during 4 eras: (1: 1973-1984; n = 27), (2: 1985-1994; n = 93), (3: 1995-2004; n = 28), and (4: 2005-2020; n = 10). Results Of the 1176 patients who had a Fontan operation, 158 (14%) had a heterotaxy syndrome. The median age at the time of Fontan was 8 (9) years. Early mortality was 20% and was greater in patients with asplenia compared to polysplenia (27% vs. 12%, p = .019). But it substantially improved over time (61% in era 1 vs. 7%-10% in the more recent eras ( p < .001)), as did transplant-free survival (22% at 10 years in era 1 vs. 88% in era 4, p < .001). Transplant-free survival was significantly lower in patients with asplenia versus those with polysplenia ( p = .014), and patients with heterotaxy had lower survival than nonheterotaxy ( p = .01). This was largely due to the asplenia group ( p < .001) (hazard ratio = 3.05, p = .007). Conclusions After Fontan operation, patients with heterotaxy, particularly asplenia, continue to demonstrate worse transplant-free survival than nonheterotaxy patients. Early mortality and long-term transplant-free survival have improved in more recent eras.
Transitioning to an Attending Congenital Heart Surgeon: The Journey has Just Begun!
Stephens, Elizabeth H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | June 25, 2022 | Volume: 13 | Issue: 4 | Pages: 536-538

10.1177/21501351221090994 | PMID 35757948 Get It

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study
Kosiorek, Heidi , Scherber, Robyn M. , Geyer, Holly L. , Verstovšek, Srđan , Langlais, Blake, Mazza, Gina L. , Gupta, Vikas , Padrnos, Leslie , Palmer, Jeanne , Fleischman, Angela, Dueck, Amylou C. , Kosiorek, Heidi E , Langlais, Blake T., Gupta, Vikas , Padrnos, Leslie J , Palmer, Jeanne M., Mesa, Ruben , Dueck, A. C. , Verstovsek, Srdan , Mazza, Gina L , Gotlib, Jason , Mesa, Ruben A.

Mayo Clinic

British Journal of Haematology | June 25, 2022 | Volume: 198 | Issue: 6 | Pages: 1065-1068

10.1111/bjh.18329 | PMID 35751150 Get It

Donation after circulatory death and lung transplantation
Santos, Pedro Reck dos , Teixeira, Paulo José Zimermann , Neto, Daniel Messias de Moraes , Cypel, Marcelo , Santos, Pedro Augusto Reck Dos , Moraes Neto, Daniel Messias de

Mayo Clinic

Jornal Brasileiro de Pneumologia | June 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: e20210369

10.36416/1806-3756/e20210369 | PMID 35475865 Get It

Lung transplantation is the most effective modality for the treatment of patients with end-stage lung diseases. Unfortunately, many people cannot benefit from this therapy due to insufficient donor availability. In this review and update article, we discuss donation after circulatory death (DCD), which is undoubtedly essential among the strategies developed to increase the donor pool. However, there are ethical and legislative considerations in the DCD process that are different from those of donation after brain death (DBD). Among others, the critical aspects of DCD are the concept of the end of life, cessation of futile treatments, and withdrawal of life-sustaining therapy. In addition, this review describes a rationale for using lungs from DCD donors and provides some important definitions, highlighting the key differences between DCD and DBD, including physiological aspects pertinent to each category. The unique ability of lungs to maintain cell viability without circulation, assuming that oxygen is supplied to the alveoli-an essential aspect of DCD-is also discussed. Furthermore, an updated review of the clinical experience with DCD for lung transplantation across international centers, recent advances in DCD, and some ethical dilemmas that deserve attention are also reported.
Accurate Identification of Subclones in Tumor Genomes
Ahmadinejad, Navid , Troftgruben, Shayna, Wang, Junwen , Chandrashekar, Pramod Bharadwaj , Dinu, Valentin , Maley, Carlo C. , Liu, Li , Chandrashekar, Pramod B , Maley, Carlo C. , Dinu, Valentin , Wang, Junwen , Liu, Li

Mayo Clinic

Molecular Biology and Evolution | June 24, 2022 | Volume: 39 | Issue: 7 | Pages: No page available

10.1093/molbev/msac136 | PMID 35749590 Get It

AbstractUnderstanding intratumor heterogeneity is critical for studying tumorigenesis and designing personalized treatments. To decompose the mixed cell population in a tumor, subclones are inferred computationally based on variant allele frequency (VAF) from bulk sequencing data. In this study, we showed that sequencing depth, mean VAF, and variance of VAF of a subclone are confounded. Without considering this effect, current methods require deep-sequencing data (&gt;300× depth) to reliably infer subclones. Here, we present a novel algorithm that incorporates depth-variance and mean-variance dependencies in a clustering error model and successfully identifies subclones in tumors sequenced at depths of as low as 30×. We implemented the algorithm as a model-based adaptive grouping of subclones (MAGOS) method. Analyses of computer simulated data and empirical sequencing data showed that MAGOS outperformed existing methods on minimum sequencing depth, decomposition accuracy, and computation efficiency. The most prominent improvements were observed in analyzing tumors sequenced at depths between 30× and 200×, whereas the performance was comparable between MAGOS and existing methods on deeply sequenced tumors. MAGOS supports analysis of single-nucleotide variants and copy number variants from a single sample or multiple samples of a tumor. We applied MAGOS to whole-exome data of late-stage liver cancers and discovered that high subclone count in a tumor was a significant risk factor of poor prognosis. Lastly, our analysis suggested that sequencing multiple samples of the same tumor at standard depth is more cost-effective and robust for subclone characterization than deep sequencing a single sample. MAGOS is available at github (https://github.com/liliulab/magos).
Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
Parney, Ian F. , Anderson, S. Keith , Gustafson, Michael P. , Steinmetz, Susan, Peterson, Timothy E., Kroneman, Trynda, Buckner, Jan C. , Solseth, Mary L., Dietz, Allan B. , Kroneman, Trynda N, Raghunathan, Aditya , Buckner, Jan C , Solseth, Mary, Parney, Ian F , Dietz, Allan B , Anderson, S Keith , Steinmetz, Susan, Raghunathan, Aditya , O’Neill, Brian Patrick

Mayo Clinic

Neuro-Oncology Advances | June 24, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac089 | PMID 35967100 Get It

Abstract Background Glioblastoma (GBM) has poor prognosis despite aggressive treatment. Dendritic cell (DC) vaccines are promising, but widespread clinical use has not been achieved, possibly reflecting manufacturing issues of antigen choice and DC potency. We previously optimized vaccine manufacture utilizing allogeneic human GBM tumor cell lysate and potent, mature autologous DCs. Here, we report a phase I study using this optimized DC vaccine in combination with standard therapy. Methods Following surgical resection and radiation with concurrent temozolomide (TMZ), newly diagnosed adult GBM patients received intradermal DC vaccines plus TMZ. Primary endpoints were safety and feasibility. Immune and treatment responses were recorded. Results Twenty-one patients were enrolled in this study. One progressed between leukapheresis and vaccine manufacture. Twenty patients received treatment per protocol. Vaccine doses (≥15) were generated following a single leukapheresis for each patient. No dose-limiting vaccine toxicities were encountered. One patient had symptomatic, histologically proven pseudoprogression. Median progression-free survival was 9.7 months. Median overall survival was 19 months. Overall survival was 25% at 2 years and 10% at 4 years. One patient remains progression-free 5 years after enrollment. Specific CD8 T-cell responses for the tumor-associated antigen gp100 were seen post-vaccination. Patients entered the trial with a leukocyte deficit compared to healthy donors which partly normalized over the course of therapy. Conclusions This vaccine platform is safe and highly feasible in combination with standard therapy for newly diagnosed patients. Imaging, histological, survival, and immunological data suggest a positive biological response to therapy that warrants further investigation.